UK launches dementia registry to support trials and life sciences investment

Traders Union
All News
Financial News
UK dementia registry launch

Highlights

BARBARA, a national dementia registry combining 180 research databases, aims to accelerate and streamline dementia trial recruitment across the UK.
Only 173 Alzheimer's patients participated in late-stage, commercially sponsored trials in England between 2024 and 2025, highlighting significant trial recruitment challenges.
The registry targets improved trial economics and global investment attractiveness for UK life sciences, with platform funding details to be announced later in 2024.

Registry rollout targets faster trial recruitment

As reported by Financial Times, the new platform, called BARBARA, will combine 180 existing research databases and population health studies into a single national registry intended to make dementia trial recruitment more efficient.

The initiative is named the Brain Ageing Registry for Biomarkers, Access to trials, Research and Adoption, in memory of actress Dame Barbara Windsor, who died with Alzheimer's disease in 2020. James Bethell, former innovation minister at the Department of Health and Social Care and chair of the project, says the system is designed to become a leading dementia data register for companies developing treatments while also giving patients and at-risk people a better chance to join research.

Bethell says one of the biggest obstacles in clinical research is identifying suitable participants quickly and accurately. He adds that only 173 people with Alzheimer's took part in late-stage, commercially sponsored trials in England between 2024 and 2025, a figure he describes as alarmingly low.

The project is intended to work alongside advances in blood biomarkers that could identify dementia before symptoms appear, making it easier to enrol people at a very early stage or even before diagnosis. Bethell argues this could eventually support a new generation of precision therapies based on genetic analysis.

Sector impact and investment ambitions

Globally, 158 Alzheimer's treatments are being tested across 192 clinical trials, while additional therapies for non-Alzheimer's dementias are also in development. Bethell says improving recruitment rates could materially change the economics of clinical trials and make the UK more attractive for pharmaceutical groups considering where to run studies and early-stage development.

He says the sector has faced a difficult period, including trade tensions with the U.S. over drug pricing and negative industry reaction after the National Institute for Health and Care Excellence ruled that Alzheimer's drugs lecanemab and donanemab did not offer value for money. Although that NICE decision is under review, Bethell suggests BARBARA gives the UK a chance to show continued support for medical innovation.

He predicts dementia treatment is entering a period of rapid change, with several promising interventions likely to emerge within five years, ranging from medicines and vaccines to better understanding of risk factors such as insufficient sleep. The amount to be invested in the platform is due to be announced later this year.

Sally John, senior vice-president for Informatics and predictive sciences at Bristol Myers Squibb, says the registry will help researchers ask better questions and generate unique datasets that can be analysed with advanced artificial intelligence and machine learning tools.

Our earlier article covered the UK’s plan to join the EU’s €60 billion defence loan scheme for Ukraine as part of a broader post‑Brexit reset with Europe. We noted that the structure would link the UK’s financial contribution to contracts awarded to British defence firms, strengthening access to Ukrainian procurement while deepening cooperation with European partners.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.